Valion Bio, Inc. (VBIO) Profit Breakdown
- 2026-06-30: Biopharma -$633.00K; Cdmo $0.00.
- 2025-06-30: Biopharma $3.00K; Cdmo $0.00.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2021-03-31 to 2026-06-30
- Data captured
Profit by product
Nonoperating Income (Expense): each quarter (3 month)
| Quarter end | Biopharma | Cdmo |
|---|---|---|
| 2026-06-30 | -$633.00K | $0.00 |
| 2025-06-30 | $3.00K | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |